Understanding the origins of medulloblastoma
Medulloblastoma is the most common high-grade brain tumour occurring in children. Medulloblastomas are divided into the following sub-groups based on different clinical and biological characteristics: WNT, SHH, Group 3 and Group 4. Group 3 and 4 medulloblastomas account for approximately 60% of all diagnoses and are often associated with poor outcomes. The poor outcomes can be attributed to a lack of accurate preclinical models, which are crucial to test new treatments before clinical trials. Thus, it is important to conduct further research to characterise Group 3 and 4 medulloblastomas to create accurate preclinical models.
Deciphering the cellular origins of Groups 3 and 4 medulloblastomas
To create effective preclinical tumour models, it is imperative to know the cells from which the tumours originate. While it is known which cells WNT and SHH medulloblastomas arise from, the cellular origins of Groups 3 and 4 remain unknown. The aim of this research project, led by Dr Laure Bihannic, is to understand which cells give rise to Groups 3 and 4 medulloblastomas and use this knowledge to create accurate preclinical models for these subgroups.
To accomplish this, Dr Bihannic will study the development of the cerebellum – an area of the brain that controls coordination and balance, and is where medulloblastomas are commonly found. She will then analyse the various cells in that region and identify ones that are most similar to Groups 3 and 4 medulloblastoma cells. Using the identified cells, she will create preclinical tumour models for Groups 3 and 4.
Investing in the future of medulloblastoma research
This research project will provide a much better understanding of medulloblastomas and generate new models to test treatments. It also highlights The Charity's commitment to developing the workforce and supporting early-career researchers, as this project will be conducted as part of Dr Bihannic's post-doctoral fellowship.